Our Bullseye™ platform takes the guesswork out of skin health. We achieve deeper insights without scalpels.
Nearly 200,000 Americans are diagnosed with blood cancers such as leukemia and lymphoma every year. For these individuals, hematopoietic cell transplantation offers hope for survival. Unfortunately, transplant recipients remain at lifetime risk of Graft-Versus-Host disease (GVHD), a deadly condition with approximately 70% incidence.
GVHD manifests in the skin as sclerosis, providing a potential biomarker to detect the disease and manage treatment. However, current methods – manual palpitation, compression, suction – are imprecise and exhibit too much inter-provider variability to be clinically useful.
Bullseye™ makes quantitative measurements of skin elasticity, and is being designed for easy use by any member of the clinical staff. These data may assist in the clinical assessment of skin, facilitating earlier detection of GVHD, accurate staging of disease progression or characterization of an individual's response to therapy.*
*This statement has not been evaluated by the FDA, and Bullseye is not cleared for sale in the USA or intended for clinical diagnostic use.
Skin elasticity is driven by the amount of collagen in the dermis. As we age, the collagen degrades, and the skin loses elasticity and becomes saggy. There are various topicals, injectables and non-invasive procedures that promise to rebuild collagen.
Most people address skin aging by waiting until they can see wrinkles and fine lines. At this point, the ideal window for intervention has passed. Additionally, when choosing a therapy, it is unclear which treatment is ideal for them.
With Bullseye's easy quantification of skin elasticity and thickness, changes in skin structure may be detectable before they result in saggy skin. Understand how each individual's skin is aging may be helpful to select the appropriate anti-aging therapy, guide application, or monitor the therapeutic effect for optimal results.
MicroElastic is building the data-driven future of precision skincare by developing a handheld device that uses ultrasound to instantly quantify the physical properties of skin, replacing subjective manual palpation that is currently used in clinical practice. Our platform will unlock the potential of skin properties for various applications, ranging from precision medicine to consumer skincare.
Developed at Duke University and protected by three international patents (pending), MicroElastic's Bullseye™ technology takes proven science and shrinks it down for the point-of-care. By taking advantage of a phenomenon called Constructive Shearwave Interference (CSI), Bullseye™ devices use focused ultrasound to generate vibrations around the edge of a "virtual biopsy core", and measure those propagating vibrations as they reach they core's center. The self-amplification of these signals and unique geometry lets us safely generate and easily measure these vibrations, enabling a portable form factor fit for any clinical setting.
Chief Executive Officer
Ultrasound expert, passionate innovator. Founded MicroElastic to deliver customer-focused technology solutions to enable precision medicine.
Chief Business Officer
Head of strategy, marketing and partnerships with five years experience in medical devices sales.
Ultrasound Engineer
Biomedical engineer and lead software developer.
Chief Financial Officer
Results-oriented financial executive with more than 30 years of public accounting, corporate finance, and leadership experience
Advisor
Serial Entrepreneur and Ultrasound device commercialization expert. Founder of PocketSonics and HemoSonics. Director of Entrepreneurial Development for Pratt School of Engineering at Duke.
Lead Software Advisor
Software and Biomedical Engineer. Cloud-computing evangelist. Passionate about delivering scalable software solutions for challenging healthcare problems.
Advisor
Medical Device Entrepreneur and Executive. Raised over $35M in Venture Capital. CEO of both Cardiosolutions and Kspine.
Advisor
Serial Entrepreneur and founder, Cronos Integrated Microsystems, Nexteme Thermal Solutions, Zenalux Biomedical. Professor of the Practice of Environmental Entrepreneurship and Innovation at Duke.
Chief Scientific Advisor
Prolific researcher, ARFI Co-Inventor with 4000+ Citations and 13 patents. Professor of the Practice at Duke.
Scientific Advisor
Ultrasound signal processing expert and collaborator. Assistant Professor at UC Boulder
Dermatologist
Leading GVHD Researcher
MicroElastic has achieved its most important commercial validation to date, by fully committing its entire fleet of demo devices to clinical studies with strategic partners. The initial engagements will last several months and will yield important evidence for the utility of our technology in the context of anti-aging applications.
Our STTR-funded clinical study is now underway at Duke Health. This study will both build a baseline normagram of skin elasticity in healthy volunteers, and correlate our noninvasive measurements of elasticity against invasive gold-standard scoring of skin sclerosis via biopsy in patients with sclerotic skin disease, in particular patients with Graft-Versus-Host-Disease.
MicroElastic is excited to announce that we are launching a demo fleet of Bullseye devices in September. We are currently arranging clinical studies with partners in the skincare industry to evaluate the effects of several therapies on skin elasticity. Please contact us if you are interested in a virtual demo!
MicroElastic will be attending the American Academy of Dermatology Annual Meeting to share updates on our technology and clinical data, as well as engage with potential strategic partners. Please reach out directly if you are attending and would like to arrange a meeting. The event will be held March 20-24 at the Colorado Convention Center in Denver, CO.
MicroElastic was invited to deliver a 4-minute pitch presentation at the Venture Connect Summit, hosted by the Council for Entrepreneurial Development, and considered the premier life science event in the southeast. The event will be held March 17-19 at the Raleigh Convention Center in Raleigh, NC.
MicroElastic welcomes Kyle Langdell as Chief Business Officer. Kyle will be leading the marketing, strategy, and fundraising efforts and brings over five years of experience in the medical device industry. Kyle holds an MBA from Carnegie Mellon University and a BS in Biomedical Engineering from Duke University.
For general inquiries, please email info@microelastic.com
MicroElastic is always interested in exceptional talent. To inquire about joining the team, please email jobs@microelastic.com